O79. An intermediate sFlt-1/PlGF ratio without preeclampsia indicates preterm delivery

Abstract

Introduction Current concepts understand preeclampsia (PE) as an altered angiogenic state that is indicated by an increased sFlt-1/PlGF ratio. This ratio is a valid biomarker for the diagnosis of PE and correlates closely with the severity of the disease. A case control study developed new, gestational age-dependent cut-offs framing an intermediate zone. Objectives In this retrospective study we analysed patients in the intermediate zone with an sFlt-1/PlGF ratio between 33 and 85 ( ⩾ 34weeks) according to pregnancy outcome, PE rate, re-testing and preterm delivery. Methods All women with tested sFlt-1/PlGF ratio in clinical routine in 2012 and 2013 were included in this retrospective cohort study. SFlt-1 and PlGF concentrations were measured using the automated Elecsys® platform (Roche Diagnostics GmbH). Results Of all 553 tested woman, 86 (16%) showed an sFlt-1/PlGF ratio in the intermediate zone between 33 and 85/110. 16 of them were tested n =5), gestational diabetes, lupus erythematodes, pre-existing maternal cardiac or kidney disease, IUGR or pathological perfusion with a mean sFlt-1/PlGF ratio of 57. Re-testing was performed in 18% of all cases. Conclusions As expected, patients with ratio in the intermediate zone show an increased risk for developing PE. Notably, in patients